Levodopa, homocysteine and Parkinson’s disease: What’s the problem?

Levodopa, homocysteine and Parkinson’s disease: What’s the problem?
Parkinsonism Relat Disord. 2023 Mar 6:105357. doi: 10.1016/j.parkreldis.2023.105357. Online ahead of print.ABSTRACTElevated circulating homocysteine levels have been associated with cognitive impairment and cardio-cerebro-vascular events. Levodopa treatment of Parkinson's disease tends to further elevate circulating homocysteine levels due to the metabolism of levodopa via catechol-O-methyltransferase (COMT). COMT co-factors are vitamins B12, B6 and folic acid. Accumulating deficiencies of these vitamins are ... read more
Source: PubMedPublished on 2023-03-15By J Eric Ahlskog